Aarti Surfactants Q2 FY27: consolidated PAT ₹12.5 Cr, margins expand off weak base
PAT +703.4% YoY · revenue +62.56% · margins expanding
₹291.24 Cr
+62.56% YoY
₹12.5 Cr
+703.4% YoY
4.29%
+3.4pp YoY
₹14.76
Aarti Surfactants' consolidated revenue rose 62.6% YoY to ₹291.24 Cr in Q2 FY27 (from ₹179.17 Cr in Q2 FY26) and 6.7% QoQ (from ₹272.87 Cr in Q1 FY27). Consolidated PAT came in at ₹12.50 Cr, up from ₹1.56 Cr a year ago and ₹9.00 Cr last quarter — but the reported YoY PAT jump (+703%) is flattered by an unusually weak year-ago base, when NPM was just 0.87%. Adjusting for this quarter's ₹4.30 Cr exceptional charge, PAT would have been ~₹16.80 Cr (NPM ~5.8%), putting underlying YoY profit growth near ~980% — still base-driven, but confirming the improvement isn't purely a one-off reversal.
Q2 FY-2027 vs prior quarters
The more durable signal is operating leverage: consolidated OPM nearly doubled YoY to 10.22% from 5.23% in Q2 FY26, and improved from 7.48% in Q1 FY27, as cost of materials consumed fell to 84.7% of revenue from 97.1% a year earlier — a cost-structure shift management has not yet explained publicly (no press release was available with this filing). Reported NPM rose to 4.29% from 0.87% YoY despite absorbing the ₹4.30 Cr exceptional provision, of which the ₹2.83 Cr customs duty/penalty component ties directly to the "Customs Duty, Fine, and Penalty Order" the company flagged on 25 September 2026. A related ₹6.71 Cr customs demand from an earlier show-cause notice remains an unprovided contingent liability, pending adjudication.
The stock went into the print at ₹530, up 7.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹14.76 vs ₹1.84 a year ago and ₹10.63 last quarter
The company has no formal guidance on record, and no published sell-side estimates for this specific quarter turned up in search, so the print cannot be benchmarked against either a management target or street consensus — both read as unknown here. Alongside the results, the quarter also saw board/AGM activity: shareholders approved an MOA alteration (1 October 2026), the board reappointed key managerial personnel and added a new director following an earlier director's resignation (12 September, cited time commitments), and CRISIL upgraded the long-term bank facility rating to A-/Stable from CARE's BBB+/Stable (3 September 2026) — alongside the ₹23.23 Cr redemption of all outstanding non-convertible preference shares out of profits on 5 August 2026.
W1
₹6.71 Cr contingent customs duty matter (DRI show-cause, pending adjudication) — whether it crystallizes into a further provision in coming quarters
W2
Durability of the raw-material cost ratio improvement (84.7% of revenue this quarter vs 97.1% a year ago) into Q3 FY27
W3
Whether OPM holds near the ~10% level reached this quarter or reverts toward the 5-7.5% band seen in the trailing four quarters
Both statements unaudited (limited review); current quarter carries a ₹4.30 Cr exceptional charge (₹1.47 Cr stamp duty on a scheme of demerger + ₹2.83 Cr customs duty/interest/penalty under a DRI order) absent in the year-ago quarter; standalone vs consolidated PAT differ by <1% (consolidation adds dormant US subsidiary Precision Ingredients USA Inc., not yet operational, and Aarti HPC Limited).